Recent Progress of Vaccines for Respiratory Syncytial Virus (RSV)

Dear Colleagues,

Respiratory Syncytial Virus (RSV) causes significant morbidity and mortality globally. In recent years, there have been notable advancements in RSV vaccine development, including the recent approval of the first RSV vaccines for pregnant women and older adults, as well as a long-acting monoclonal antibody product for infants.

This Special Issue compiles cutting-edge research, clinical trial findings, implementation strategies, and policy discussions centered around the evolving landscape of RSV immunization products. Topics covered include recent clinical trial data, duration of protection, vaccine uptake, and real-world evidence of vaccine effectiveness.

By emphasizing multidisciplinary efforts across clinical trials, basic science, epidemiology, and public health, this issue aims to inform the global response to RSV and its prevention strategies, promoting the integration of new evidence into national immunization programs across various countries. We welcome contributions that address both scientific innovations and the implementation challenges faced in diverse healthcare settings.

Dr. Ting Shi
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.